eResearchTechnology (eRT) has filed for an initial public offering as part of an overall effort to reposition its parent company, Premier Research Worldwide (PRWW), as a provider of Internet clinical
eResearchTechnology (eRT) has filed for an initial public offering as part of an overall effort to reposition its parent company, Premier Research Worldwide (PRWW), as a provider of Internet clinical trials software. Philadelphia-based eRT provides diagnostic services and research capabilities over the Internet to accelerate clinical research trials. Its products are combined into electronic research networks, which connect sponsors, clinical research organizations, physicians, and patients via proprietary database technology and software.
In addition to filing the eRT IPO last month, PRWW recently sold off its clinical research organization, launched eRT, acquired 10% of a Web-hosting company called Medical Advisory Systems, and announced a five-year contract between eRT and MAS whereby MAS will provide application hosting for eRTs products. PRWW will funnel its business offerings through the eRT subsidiary, and essentially act as a holding company. MAS, which is also the ASP for americasdoctor.com on AOL, will use part of the PRWW investment to upgrade its equipment to host eRTs applications and will allow eRT to access MASs 24/7 physician call center as support for several eRT programs, including eSafetyNet and eECG.
© 2000 Miller Freeman, Inc., a United News & Media company.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.